{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', '15', 'CLINICAL TRIAL PROTOCOL AMENDMENTS', 'All appendices attached hereto and referred to herein are made part of this clinical trial protocol.', 'The Investigator should not implement any deviation from, or changes to the clinical trial protocol', 'without agreement by the Sponsor and prior review and documented approval/favorable opinion', 'from the IRB/IEC and/or notification/approval of health authorities (competent regulatory', 'authority) of an amendment, as required by local regulation, except where necessary to eliminate', 'an immediate hazard(s) to clinical trial patients, or when the change(s) involves only logistical or', 'administrative aspects of the trial. Any change agreed upon will be recorded in writing, the', 'written amendment will be signed by the Investigator and by the Sponsor and the signed', 'amendment will be filed with this clinical trial protocol.', 'Any amendment to the clinical trial protocol requires written approval/favorable opinion by the', 'IRB/IEC prior to its implementation, unless there are overriding safety reasons.', 'In case of substantial amendment to the clinical trial protocol, approval from the health authorities', '(competent regulatory authority) will be sought before implementation.', 'In some instances, an amendment may require a change to the ICF. The Investigator must receive', 'an IRB/IEC approval/favorable opinion concerning the revised ICF prior to implementation of the', 'change and patient signature should be re-collected if necessary.', 'Property of the Sanofi Group - strictly confidential', 'Page 132', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', '16', 'BIBLIOGRAPHIC REFERENCES', '1. Global initiative for asthma. Difficult to treat and severe asthma in adolescents and adults', 'patients. A GINA pocket guide for Health Profesionnals. Diagnosis and management. V2.0', 'April 2019. Available at https://ginasthma.org/wp-content/uploads/2019/04/GINA-Severe-', 'asthma-Pocket-Guide-v2.0-wms-l.pdf. Last accessed on 16 July 2019.', '2. Nordlund B, Melen E, Schultz ES. Prevalence of severe childhood asthma according to the', 'WHO. Respir Med. 2014;108(8): 1234-7.', '3. Hedlin G, Bush A, Lodrup Carlsen K. Problematic severe asthma in children, not one', 'problem but many: a GA2LEN initiative. Eur Respir J. 2010;36(1):196-20', '4. Levine SJ, Wenzel SE. Narrative review: The role of Th2 immune pathway modulation in the', 'treatment of severe asthma and its phenotypes. Ann Intern Med. 2010;152:232-7.', '5. Liptrott NJ, Penny M, Bray PG, Sathish J, Khoo SH, Back DJ, et al. The impact of cytokines', 'on the expression of drug transporters, cytochrome P 450 enzymes and chemokine receptors in', 'human PBMC. British Journal of Pharmacology. 2009;156(3):497-508', '6. Christensen H, Hermann M. Immunological response as a source to variability in drug', 'metabolism and transport. 2012 Frontiers in pharmacology, February 2012, Vol 3, Art 8.', '7. Abdel-Razzak Z, Loyer P, Fautrel A, Gautier JC, Corcos L, Turlin B, et al. Cytokines down-', 'regulate expression of major cytochrome p-450 enzymes in adult human hepatocytes in', 'primary culture. Mol. Pharmacol. 1993;44(4):707-15.', '8. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coateset A, et al. Standardization', 'of spirometry. Series \"ATS/ERS TASK FORCE: Standardization of Lung Function Testing\"', 'Edited by Brusasco V, Crapo R, and Viegi G. Eur Resir J. 2005;26:319-38.', '9. Norman GR, Sloan JA, Wyrwich KW. Point/Counterpoint, Interpretation of Changes in', 'Health-related Quality of Life, The Remarkable Universality of Half a Standard Deviation', 'Medical Care. 2003;41(5):582-92.', \"10. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a\", 'questionnaire to measure asthma control. Eur Respir J. 1999;14(4):902-7.', '11. Juniper EH, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a', 'disease-specific quality of life questionnaire. J Clin Epidemiol. 1994;47(1):81-7.', 'Property of the Sanofi Group - strictly confidential', 'Page 133', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}